Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-05-11

AUTHORS

Rory J. McCrimmon, Karen Palmer, Abdul Jabbar Omar Alsaleh, Elisheva Lew, Amar Puttanna

ABSTRACT

IntroductioniGlarLixi is indicated as an adjunct to diet and exercise in addition to metformin (with or without sodium-glucose cotransporter-2 inhibitors) to improve glycemic control in adults with insufficiently controlled type 2 diabetes (T2D). A cost-effectiveness analysis was conducted to compare iGlarLixi with premix biphasic insulin aspart 30 (BIAsp 30) in people with T2D suboptimally controlled with basal insulin (BI).MethodsThe IQVIA CORE Diabetes Model was used to estimate lifetime costs and outcomes for people with T2D from a UK health care perspective at a willingness-to-pay threshold of £20,000. Initial clinical data were based on the phase 3 randomized, open-label, active-controlled SoliMix clinical trial which compared the efficacy and safety of once-daily iGlarLixi with that of twice-daily BIAsp 30. Costs associated with management and complications and utilities values were derived from published sources. Lifetime costs (in £GBP) and quality-adjusted life-years (QALYs) were predicted; extensive scenario and sensitivity analyses were conducted.ResultsEstimated QALYs gained were slightly higher with iGlarLixi (8.9 vs. 8.8) compared with premix BIAsp 30, at a higher cost (£23,204 vs. £21,961). The base case incremental cost-effectiveness ratio (ICER) per QALY was £13,598. Treatment acquisition was the main driver of cost differences (iGlarLixi, £11,750; premix BIAsp 30, £10,395). Costs associated with management and complications were generally similar between comparators.ConclusioniGlarLixi provides improved QALY outcomes at an acceptable cost compared with premix BIAsp 30, with an ICER below the threshold generally considered acceptable by UK authorities. In people with T2D, iGlarLixi is a simple, cost-effective option for advancing therapy of BI, with fewer daily injections than premix BIAsp 30. More... »

PAGES

1203-1214

References to SciGraph publications

  • 2013-06-22. UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82 in DIABETOLOGIA
  • 2021-10-29. Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK in DIABETES THERAPY
  • 2021-04-15. The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease in DIABETES THERAPY
  • 2015-09-09. Geographic patterns in patient demographics and insulin use in 18 countries, a global perspective from the multinational observational study assessing insulin use: understanding the challenges associated with progression of therapy (MOSAIc) in BMC ENDOCRINE DISORDERS
  • 2019-05-16. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting in DIABETES THERAPY
  • 2021-10-29. Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy in DIABETES THERAPY
  • 2018-03-24. Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review in DIABETES THERAPY
  • 2020-07-22. Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK in DIABETES THERAPY
  • 2005-05. BRIEF REPORT: The burden of diabetes therapy in JOURNAL OF GENERAL INTERNAL MEDICINE
  • 2004-10-27. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) in DIABETOLOGIA
  • 2021-01-09. Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting in DIABETES THERAPY
  • 2019-10-10. Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease in DIABETES THERAPY
  • 2014-03-22. The association between the measurement of adherence to anti-diabetes medicine and the HbA1c in INTERNATIONAL JOURNAL OF CLINICAL PHARMACY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s13300-022-01267-3

    DOI

    http://dx.doi.org/10.1007/s13300-022-01267-3

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1147780831

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/35543869


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Systems Medicine, School of Medicine, University of Dundee, Dundee, UK", 
              "id": "http://www.grid.ac/institutes/grid.8241.f", 
              "name": [
                "Systems Medicine, School of Medicine, University of Dundee, Dundee, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "McCrimmon", 
            "givenName": "Rory J.", 
            "id": "sg:person.01252203221.14", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252203221.14"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Sanofi, Reading, UK", 
              "id": "http://www.grid.ac/institutes/grid.476716.5", 
              "name": [
                "Sanofi, Reading, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Palmer", 
            "givenName": "Karen", 
            "id": "sg:person.011712243313.22", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011712243313.22"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Sanofi, Milan, Italy", 
              "id": "http://www.grid.ac/institutes/grid.476719.a", 
              "name": [
                "Sanofi, Milan, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Alsaleh", 
            "givenName": "Abdul Jabbar Omar", 
            "id": "sg:person.07361124447.08", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07361124447.08"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Sanofi, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.417924.d", 
              "name": [
                "Sanofi, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lew", 
            "givenName": "Elisheva", 
            "id": "sg:person.014166167707.92", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014166167707.92"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Good Hope Hospital, Birmingham, UK", 
              "id": "http://www.grid.ac/institutes/grid.412926.a", 
              "name": [
                "Sanofi, Reading, UK", 
                "Good Hope Hospital, Birmingham, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Puttanna", 
            "givenName": "Amar", 
            "id": "sg:person.01163666524.04", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163666524.04"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1111/j.1525-1497.2005.0117.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040515620", 
              "https://doi.org/10.1111/j.1525-1497.2005.0117.x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-020-00883-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1129560870", 
              "https://doi.org/10.1007/s13300-020-00883-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00125-004-1527-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036304902", 
              "https://doi.org/10.1007/s00125-004-1527-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11096-014-9929-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033681669", 
              "https://doi.org/10.1007/s11096-014-9929-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-019-00701-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1121657302", 
              "https://doi.org/10.1007/s13300-019-00701-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-019-0630-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1114500568", 
              "https://doi.org/10.1007/s13300-019-0630-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-018-0395-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1101747506", 
              "https://doi.org/10.1007/s13300-018-0395-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s12902-015-0044-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010802675", 
              "https://doi.org/10.1186/s12902-015-0044-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-020-00989-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1134461617", 
              "https://doi.org/10.1007/s13300-020-00989-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-021-01040-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1137230210", 
              "https://doi.org/10.1007/s13300-021-01040-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00125-013-2940-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010988781", 
              "https://doi.org/10.1007/s00125-013-2940-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-021-01159-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1142247937", 
              "https://doi.org/10.1007/s13300-021-01159-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-021-01156-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1142247938", 
              "https://doi.org/10.1007/s13300-021-01156-1"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2022-05-11", 
        "datePublishedReg": "2022-05-11", 
        "description": "IntroductioniGlarLixi is indicated as an adjunct to diet and exercise in addition to metformin (with or without sodium-glucose cotransporter-2 inhibitors) to improve glycemic control in adults with insufficiently controlled type 2 diabetes (T2D). A cost-effectiveness analysis was conducted to compare iGlarLixi with premix biphasic insulin aspart 30 (BIAsp 30) in people with T2D suboptimally controlled with basal insulin (BI).MethodsThe IQVIA CORE Diabetes Model was used to estimate lifetime costs and outcomes for people with T2D from a UK health care perspective at a willingness-to-pay threshold of \u00a320,000. Initial clinical data were based on the phase 3 randomized, open-label, active-controlled SoliMix clinical trial which compared the efficacy and safety of once-daily iGlarLixi with that of twice-daily BIAsp 30. Costs associated with management and complications and utilities values were derived from published sources. Lifetime costs (in \u00a3GBP) and quality-adjusted life-years (QALYs) were predicted; extensive scenario and sensitivity analyses were conducted.ResultsEstimated QALYs gained were slightly higher with iGlarLixi (8.9 vs. 8.8) compared with premix BIAsp 30, at a higher cost (\u00a323,204 vs. \u00a321,961). The base case incremental cost-effectiveness ratio (ICER) per QALY was \u00a313,598. Treatment acquisition was the main driver of cost differences (iGlarLixi, \u00a311,750; premix BIAsp 30, \u00a310,395). Costs associated with management and complications were generally similar between comparators.ConclusioniGlarLixi provides improved QALY outcomes at an acceptable cost compared with premix BIAsp 30, with an ICER below the threshold generally considered acceptable by UK authorities. In people with T2D, iGlarLixi is a simple, cost-effective option for advancing therapy of BI, with fewer daily injections than premix BIAsp 30.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s13300-022-01267-3", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1044057", 
            "issn": [
              "1869-6953", 
              "1869-6961"
            ], 
            "name": "Diabetes Therapy", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "6", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "13"
          }
        ], 
        "keywords": [
          "incremental cost-effectiveness ratio", 
          "BIAsp 30", 
          "basal insulin", 
          "biphasic insulin aspart 30", 
          "base-case incremental cost-effectiveness ratio", 
          "daily BIAsp 30", 
          "insulin aspart 30", 
          "initial clinical data", 
          "type 2 diabetes", 
          "lifetime costs", 
          "health care perspective", 
          "cost-effectiveness ratio", 
          "cost-effectiveness analysis", 
          "glycemic control", 
          "daily injections", 
          "clinical trials", 
          "IQVIA CORE", 
          "clinical data", 
          "treatment acquisition", 
          "iGlarLixi", 
          "type 2", 
          "QALY outcomes", 
          "care perspective", 
          "T2D", 
          "phase 3", 
          "cost-effective option", 
          "complications", 
          "insulin", 
          "cost differences", 
          "outcomes", 
          "patients", 
          "diabetes", 
          "metformin", 
          "therapy", 
          "utility values", 
          "QALY", 
          "adjunct", 
          "QALYs", 
          "trials", 
          "efficacy", 
          "adults", 
          "management", 
          "injection", 
          "exercise", 
          "people", 
          "safety", 
          "options", 
          "threshold", 
          "high cost", 
          "differences", 
          "acceptable cost", 
          "comparator", 
          "control", 
          "sensitivity analysis", 
          "analysis", 
          "UK", 
          "data", 
          "addition", 
          "willingness", 
          "ratio", 
          "extensive scenarios", 
          "cost", 
          "acquisition", 
          "values", 
          "model", 
          "perspective", 
          "main drivers", 
          "source", 
          "drivers", 
          "UK authorities", 
          "authorities", 
          "scenarios", 
          "core"
        ], 
        "name": "Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK", 
        "pagination": "1203-1214", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1147780831"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s13300-022-01267-3"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "35543869"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s13300-022-01267-3", 
          "https://app.dimensions.ai/details/publication/pub.1147780831"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-08-04T17:11", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_932.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s13300-022-01267-3"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01267-3'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01267-3'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01267-3'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01267-3'


     

    This table displays all metadata directly associated to this object as RDF triples.

    227 TRIPLES      21 PREDICATES      111 URIs      90 LITERALS      7 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s13300-022-01267-3 schema:about anzsrc-for:11
    2 anzsrc-for:1103
    3 schema:author N4a3703e69bd0406f97ad4b613329f9c7
    4 schema:citation sg:pub.10.1007/s00125-004-1527-z
    5 sg:pub.10.1007/s00125-013-2940-y
    6 sg:pub.10.1007/s11096-014-9929-6
    7 sg:pub.10.1007/s13300-018-0395-3
    8 sg:pub.10.1007/s13300-019-00701-3
    9 sg:pub.10.1007/s13300-019-0630-6
    10 sg:pub.10.1007/s13300-020-00883-1
    11 sg:pub.10.1007/s13300-020-00989-6
    12 sg:pub.10.1007/s13300-021-01040-y
    13 sg:pub.10.1007/s13300-021-01156-1
    14 sg:pub.10.1007/s13300-021-01159-y
    15 sg:pub.10.1111/j.1525-1497.2005.0117.x
    16 sg:pub.10.1186/s12902-015-0044-z
    17 schema:datePublished 2022-05-11
    18 schema:datePublishedReg 2022-05-11
    19 schema:description IntroductioniGlarLixi is indicated as an adjunct to diet and exercise in addition to metformin (with or without sodium-glucose cotransporter-2 inhibitors) to improve glycemic control in adults with insufficiently controlled type 2 diabetes (T2D). A cost-effectiveness analysis was conducted to compare iGlarLixi with premix biphasic insulin aspart 30 (BIAsp 30) in people with T2D suboptimally controlled with basal insulin (BI).MethodsThe IQVIA CORE Diabetes Model was used to estimate lifetime costs and outcomes for people with T2D from a UK health care perspective at a willingness-to-pay threshold of £20,000. Initial clinical data were based on the phase 3 randomized, open-label, active-controlled SoliMix clinical trial which compared the efficacy and safety of once-daily iGlarLixi with that of twice-daily BIAsp 30. Costs associated with management and complications and utilities values were derived from published sources. Lifetime costs (in £GBP) and quality-adjusted life-years (QALYs) were predicted; extensive scenario and sensitivity analyses were conducted.ResultsEstimated QALYs gained were slightly higher with iGlarLixi (8.9 vs. 8.8) compared with premix BIAsp 30, at a higher cost (£23,204 vs. £21,961). The base case incremental cost-effectiveness ratio (ICER) per QALY was £13,598. Treatment acquisition was the main driver of cost differences (iGlarLixi, £11,750; premix BIAsp 30, £10,395). Costs associated with management and complications were generally similar between comparators.ConclusioniGlarLixi provides improved QALY outcomes at an acceptable cost compared with premix BIAsp 30, with an ICER below the threshold generally considered acceptable by UK authorities. In people with T2D, iGlarLixi is a simple, cost-effective option for advancing therapy of BI, with fewer daily injections than premix BIAsp 30.
    20 schema:genre article
    21 schema:isAccessibleForFree true
    22 schema:isPartOf N44ca1bb2c0834b728075b9c3e1f4f5a3
    23 N4e08b964946d42758bfe968fa360a8df
    24 sg:journal.1044057
    25 schema:keywords BIAsp 30
    26 IQVIA CORE
    27 QALY
    28 QALY outcomes
    29 QALYs
    30 T2D
    31 UK
    32 UK authorities
    33 acceptable cost
    34 acquisition
    35 addition
    36 adjunct
    37 adults
    38 analysis
    39 authorities
    40 basal insulin
    41 base-case incremental cost-effectiveness ratio
    42 biphasic insulin aspart 30
    43 care perspective
    44 clinical data
    45 clinical trials
    46 comparator
    47 complications
    48 control
    49 core
    50 cost
    51 cost differences
    52 cost-effective option
    53 cost-effectiveness analysis
    54 cost-effectiveness ratio
    55 daily BIAsp 30
    56 daily injections
    57 data
    58 diabetes
    59 differences
    60 drivers
    61 efficacy
    62 exercise
    63 extensive scenarios
    64 glycemic control
    65 health care perspective
    66 high cost
    67 iGlarLixi
    68 incremental cost-effectiveness ratio
    69 initial clinical data
    70 injection
    71 insulin
    72 insulin aspart 30
    73 lifetime costs
    74 main drivers
    75 management
    76 metformin
    77 model
    78 options
    79 outcomes
    80 patients
    81 people
    82 perspective
    83 phase 3
    84 ratio
    85 safety
    86 scenarios
    87 sensitivity analysis
    88 source
    89 therapy
    90 threshold
    91 treatment acquisition
    92 trials
    93 type 2
    94 type 2 diabetes
    95 utility values
    96 values
    97 willingness
    98 schema:name Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK
    99 schema:pagination 1203-1214
    100 schema:productId N22cfd9b98883465bb1d36c6c645958a1
    101 Ndccc65fcd7e34f5793102e515e6842fc
    102 Neee292eef7ea41399e47b25001bacecb
    103 schema:sameAs https://app.dimensions.ai/details/publication/pub.1147780831
    104 https://doi.org/10.1007/s13300-022-01267-3
    105 schema:sdDatePublished 2022-08-04T17:11
    106 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    107 schema:sdPublisher N008fa0b6eb6246848d40ea82160e1b12
    108 schema:url https://doi.org/10.1007/s13300-022-01267-3
    109 sgo:license sg:explorer/license/
    110 sgo:sdDataset articles
    111 rdf:type schema:ScholarlyArticle
    112 N008fa0b6eb6246848d40ea82160e1b12 schema:name Springer Nature - SN SciGraph project
    113 rdf:type schema:Organization
    114 N0d5922e5f81e43cf985c842b7a2a9458 rdf:first sg:person.011712243313.22
    115 rdf:rest N64414cd7e810469086e534f184829c6f
    116 N22cfd9b98883465bb1d36c6c645958a1 schema:name doi
    117 schema:value 10.1007/s13300-022-01267-3
    118 rdf:type schema:PropertyValue
    119 N44ca1bb2c0834b728075b9c3e1f4f5a3 schema:volumeNumber 13
    120 rdf:type schema:PublicationVolume
    121 N4788b902e65b402ca9410d4e02812dbf rdf:first sg:person.01163666524.04
    122 rdf:rest rdf:nil
    123 N4a3703e69bd0406f97ad4b613329f9c7 rdf:first sg:person.01252203221.14
    124 rdf:rest N0d5922e5f81e43cf985c842b7a2a9458
    125 N4e08b964946d42758bfe968fa360a8df schema:issueNumber 6
    126 rdf:type schema:PublicationIssue
    127 N64414cd7e810469086e534f184829c6f rdf:first sg:person.07361124447.08
    128 rdf:rest N8b4efca3f0d9448fb971025f63078542
    129 N8b4efca3f0d9448fb971025f63078542 rdf:first sg:person.014166167707.92
    130 rdf:rest N4788b902e65b402ca9410d4e02812dbf
    131 Ndccc65fcd7e34f5793102e515e6842fc schema:name pubmed_id
    132 schema:value 35543869
    133 rdf:type schema:PropertyValue
    134 Neee292eef7ea41399e47b25001bacecb schema:name dimensions_id
    135 schema:value pub.1147780831
    136 rdf:type schema:PropertyValue
    137 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    138 schema:name Medical and Health Sciences
    139 rdf:type schema:DefinedTerm
    140 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    141 schema:name Clinical Sciences
    142 rdf:type schema:DefinedTerm
    143 sg:journal.1044057 schema:issn 1869-6953
    144 1869-6961
    145 schema:name Diabetes Therapy
    146 schema:publisher Springer Nature
    147 rdf:type schema:Periodical
    148 sg:person.01163666524.04 schema:affiliation grid-institutes:grid.412926.a
    149 schema:familyName Puttanna
    150 schema:givenName Amar
    151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163666524.04
    152 rdf:type schema:Person
    153 sg:person.011712243313.22 schema:affiliation grid-institutes:grid.476716.5
    154 schema:familyName Palmer
    155 schema:givenName Karen
    156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011712243313.22
    157 rdf:type schema:Person
    158 sg:person.01252203221.14 schema:affiliation grid-institutes:grid.8241.f
    159 schema:familyName McCrimmon
    160 schema:givenName Rory J.
    161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252203221.14
    162 rdf:type schema:Person
    163 sg:person.014166167707.92 schema:affiliation grid-institutes:grid.417924.d
    164 schema:familyName Lew
    165 schema:givenName Elisheva
    166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014166167707.92
    167 rdf:type schema:Person
    168 sg:person.07361124447.08 schema:affiliation grid-institutes:grid.476719.a
    169 schema:familyName Alsaleh
    170 schema:givenName Abdul Jabbar Omar
    171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07361124447.08
    172 rdf:type schema:Person
    173 sg:pub.10.1007/s00125-004-1527-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1036304902
    174 https://doi.org/10.1007/s00125-004-1527-z
    175 rdf:type schema:CreativeWork
    176 sg:pub.10.1007/s00125-013-2940-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1010988781
    177 https://doi.org/10.1007/s00125-013-2940-y
    178 rdf:type schema:CreativeWork
    179 sg:pub.10.1007/s11096-014-9929-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033681669
    180 https://doi.org/10.1007/s11096-014-9929-6
    181 rdf:type schema:CreativeWork
    182 sg:pub.10.1007/s13300-018-0395-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101747506
    183 https://doi.org/10.1007/s13300-018-0395-3
    184 rdf:type schema:CreativeWork
    185 sg:pub.10.1007/s13300-019-00701-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1121657302
    186 https://doi.org/10.1007/s13300-019-00701-3
    187 rdf:type schema:CreativeWork
    188 sg:pub.10.1007/s13300-019-0630-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1114500568
    189 https://doi.org/10.1007/s13300-019-0630-6
    190 rdf:type schema:CreativeWork
    191 sg:pub.10.1007/s13300-020-00883-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1129560870
    192 https://doi.org/10.1007/s13300-020-00883-1
    193 rdf:type schema:CreativeWork
    194 sg:pub.10.1007/s13300-020-00989-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1134461617
    195 https://doi.org/10.1007/s13300-020-00989-6
    196 rdf:type schema:CreativeWork
    197 sg:pub.10.1007/s13300-021-01040-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1137230210
    198 https://doi.org/10.1007/s13300-021-01040-y
    199 rdf:type schema:CreativeWork
    200 sg:pub.10.1007/s13300-021-01156-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1142247938
    201 https://doi.org/10.1007/s13300-021-01156-1
    202 rdf:type schema:CreativeWork
    203 sg:pub.10.1007/s13300-021-01159-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1142247937
    204 https://doi.org/10.1007/s13300-021-01159-y
    205 rdf:type schema:CreativeWork
    206 sg:pub.10.1111/j.1525-1497.2005.0117.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1040515620
    207 https://doi.org/10.1111/j.1525-1497.2005.0117.x
    208 rdf:type schema:CreativeWork
    209 sg:pub.10.1186/s12902-015-0044-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1010802675
    210 https://doi.org/10.1186/s12902-015-0044-z
    211 rdf:type schema:CreativeWork
    212 grid-institutes:grid.412926.a schema:alternateName Good Hope Hospital, Birmingham, UK
    213 schema:name Good Hope Hospital, Birmingham, UK
    214 Sanofi, Reading, UK
    215 rdf:type schema:Organization
    216 grid-institutes:grid.417924.d schema:alternateName Sanofi, Paris, France
    217 schema:name Sanofi, Paris, France
    218 rdf:type schema:Organization
    219 grid-institutes:grid.476716.5 schema:alternateName Sanofi, Reading, UK
    220 schema:name Sanofi, Reading, UK
    221 rdf:type schema:Organization
    222 grid-institutes:grid.476719.a schema:alternateName Sanofi, Milan, Italy
    223 schema:name Sanofi, Milan, Italy
    224 rdf:type schema:Organization
    225 grid-institutes:grid.8241.f schema:alternateName Systems Medicine, School of Medicine, University of Dundee, Dundee, UK
    226 schema:name Systems Medicine, School of Medicine, University of Dundee, Dundee, UK
    227 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...